Last reviewed · How we verify
AGN-150998
AGN-150998 is a Small molecule drug developed by Allergan. It is currently in Phase 2 development.
AGN-150998 is a small molecule being studied as a potential treatment for Age-related Macular Degeneration and Macular Degeneration. It is being compared to ranibizumab and a sham injection in clinical trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AGN-150998 |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Anterior chamber inflammation
- Retinal pigment epithelial tear
- Urinary tract infection
- Nasopharyngitis
- Palpitations
- Ventricular extrasystoles
- Conjunctival haemorrhage
- Eye irritation
- Anterior chamber cell
- Anterior chamber flare
- Eye pain
- Hyalosis asteroid
Key clinical trials
- Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (PHASE3)
- A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (PHASE3)
- Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) (PHASE2)
- Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD (PHASE1)
- Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-150998 CI brief — competitive landscape report
- AGN-150998 updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about AGN-150998
What is AGN-150998?
Who makes AGN-150998?
What development phase is AGN-150998 in?
What are the side effects of AGN-150998?
Related
- Manufacturer: Allergan — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing